Cargando...
Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure
Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′‐GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP‐dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5...
Gardado en:
| Publicado en: | Br J Pharmacol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5758391/ https://ncbi.nlm.nih.gov/pubmed/28213937 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13749 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|